TECHNE CORPORATION ANNOUNCES THAT DR. KAREN A. HOLBROOK HAS ACCEPTED A SEAT
ON TECHNE'S BOARD

Minneapolis/February 12, 2007/--Techne Corporation (NASDAQ: TECH) today
announced that Dr. Karen A. Holbrook has accepted a Director position on
Techne's Board of Directors.  Dr. Holbrook's initial term will begin
immediately and run through October 25, 2007.  Techne's shareholders reelect
all Directors on an annual basis.

Dr. Holbrook has been the president of The Ohio State University since
October 1, 2002.   Under her direction, the University has realized its
vision of being one of the top-ranked research and teaching universities in
the country.  Ohio State's sponsored research funding is more than $650
million and it now ranks eighth among public universities in research
expenditures.   She will be resigning this position in June of 2007.
Dr. Holbrook came to Ohio State from The University of Georgia, where she
served as senior vice president for academic affairs and provost, as well as
professor of cell biology and adjunct professor of anatomy and cell biology
and medicine at the Medical College of Georgia.

Before that, Dr. Holbrook served at the University of Florida at Gainesville
as vice president for research and dean of the Graduate School, as well as
professor of anatomy and cell biology and medicine (dermatology).  She spent
the majority of her academic career as a professor of biological structure
and medicine at the University of Washington School of Medicine, where she
gained a national reputation for her expertise in human fetal skin
development and genetic skin disease and was a National Institutes of Health
(NIH) Merit awardee.  She also served as associate dean for scientific
affairs.

Dr. Holbrook has served on the Huntington Bancshares, Inc. (NASDAQ: HBAN)
Board of Directors since 2004.  In January 2007, she was appointed as a
member of the Advisory Committee to the Director of the NIH.  Dr. Holbrook
also serves on several non-profit boards, such as the American Association
for the Advancement of Science and the Association of American Medical
Colleges, among many others.

Dr. Holbrook earned her B.S. and M.S. in zoology from the University of
Wisconsin-Madison. After teaching biology at Ripon College, she earned a
Ph.D. in biological structure from the University of Washington School of
Medicine where she pursued postdoctoral training in the Department of
Medicine, Division of Dermatology.

Mr. Thomas E. Oland, TECHNE's Chairman and CEO, said "I am extremely pleased
with Dr. Holbrook's decision to accept a position on Techne's Board.  We are
very fortunate to have a person of her caliber on our Board.  I am very
confident that she will make a significant contribution to our future
success."


Forward Looking Statements:
This press release may contain forward-looking statements within the meaning
of the Private Litigation Reform Act. Forward-looking statements involve
risks and uncertainties that may affect the actual results of operations.
The following important factors, among others, have affected and, in the
future, could affect the Company's actual results: the introduction and
acceptance of new biotechnology and hematology products, the levels and
particular directions of research by the Company's customers, the impact of
the growing number of producers of biotechnology research products and
related price competition, the retention of hematology OEM (private label)
and proficiency survey business, the impact of currency exchange rate
fluctuations, and the costs and results of research and product development
efforts of the Company and of companies in which the Company has invested or
with which it has formed strategic relationships.

For additional information concerning such factors, see the Company's annual
report on Form 10-K and quarterly reports on Form 10-Q as filed with the
Securities and Exchange Commission.  We undertake no obligation to update or
revise any forward-looking statements we make in this release due to new
information or future events.  Investors are cautioned not to place undue
emphasis on these statements.
            **********************************************
Techne Corporation has two operating subsidiaries: Research and Diagnostic
Systems, Inc. (R&D Systems) of Minneapolis, Minnesota and R&D Systems Europe,
Ltd. (R&D Europe) of Abingdon, England.  R&D Systems is a specialty
manufacturer of biological products.  R&D Systems has two subsidiaries,
Fortron Bio Science, Inc. (Fortron), located in Minneapolis, and BiosPacific,
Inc. (BiosPacific), located in Emeryville, California.  Fortron develops and
manufactures antibodies and BiosPacific is a worldwide supplier of biologics
to manufacturers of in vitro diagnostic systems and immunodiagnostic kits.
R&D Europe is a distributor of biotechnology products.

Contact:   Greg Melsen, Chief Financial Officer
           Kathy Backes, Controller
        (612) 379-8854